Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dan Raghinaru

Showing results (11-20 of 44) with videos related to

Pageof 5
Sort By:
Journal of Vascular Surgery|December 19, 2012
Prediction of graft patency and mortality after distal revascularization and interval ligation for hemodialysis access-related hand ischemiaSalvatore T Scali, Catherine K Chang, Dan Raghinaru, et al.
Diabetes Care|September 15, 2025
Adults With Type 2 Diabetes Benefit From Automated Insulin Delivery Irrespective of C-Peptide LevelIrl B Hirsch, Yogish C Kudva, David T Ahn, et al.
Diabetes Technology & Therapeutics|November 6, 2020
Clinical Management and Pump Parameter Adjustment of the Control-IQ Closed-Loop Control System: Results from a 6-Month, Multicenter, Randomized Clinical TrialGrenye O'Malley, Laurel H Messer, Carol J Levy, et al.
Diabetes Care|November 20, 2025
Additive Benefits of Control-IQ+ AID to GLP-1 Receptor Agonist Use in Adults With Type 2 DiabetesTimothy E Graham, Dan Raghinaru, Samina Afreen, et al.
Journal of Diabetes Science and Technology|April 27, 2022
Outcomes in Pump- and CGM-Baseline Use Subgroups in the International Diabetes Closed-Loop TrialLaya Ekhlaspour, Dan Raghinaru, Gregory P Forlenza, et al.
Clinical Diabetes : a Publication of the American Diabetes Association|January 17, 2024
Beneficial Effects of Control-IQ Automated Insulin Delivery in Basal-Bolus and Basal-Only Insulin Users With Type 2 DiabetesCarol J Levy, Dan Raghinaru, Yogish C Kudva, et al.
Pediatric Diabetes|July 13, 2016
Ketone production in children with type 1 diabetes, ages 4-14 years, with and without nocturnal insulin pump suspensionR Paul Wadwa, H Peter Chase, Dan Raghinaru, et al.
Diabetes Technology & Therapeutics|June 11, 2021
Patient-Reported Outcomes in a Randomized Trial of Closed-Loop Control: The Pivotal International Diabetes Closed-Loop TrialYogish C Kudva, Lori M Laffel, Sue A Brown, et al.
Ophthalmology|November 20, 2013
Donor age and factors related to endothelial cell loss 10 years after penetrating keratoplasty: Specular Microscopy Ancillary Study, Jonathan H Lass, Beth Ann Benetz, et al.
JAMA Ophthalmology|October 17, 2014
Factors associated with corneal graft survival in the cornea donor study, Alan Sugar, Robin L Gal, et al.
Pageof 5

Showing results (11-20 of 44) with videos related to

Sort By:
Pageof 5
Journal of Vascular Surgery|December 19, 2012
Prediction of graft patency and mortality after distal revascularization and interval ligation for hemodialysis access-related hand ischemiaSalvatore T Scali, Catherine K Chang, Dan Raghinaru, et al.
Diabetes Care|September 15, 2025
Adults With Type 2 Diabetes Benefit From Automated Insulin Delivery Irrespective of C-Peptide LevelIrl B Hirsch, Yogish C Kudva, David T Ahn, et al.
Diabetes Technology & Therapeutics|November 6, 2020
Clinical Management and Pump Parameter Adjustment of the Control-IQ Closed-Loop Control System: Results from a 6-Month, Multicenter, Randomized Clinical TrialGrenye O'Malley, Laurel H Messer, Carol J Levy, et al.
Diabetes Care|November 20, 2025
Additive Benefits of Control-IQ+ AID to GLP-1 Receptor Agonist Use in Adults With Type 2 DiabetesTimothy E Graham, Dan Raghinaru, Samina Afreen, et al.
Journal of Diabetes Science and Technology|April 27, 2022
Outcomes in Pump- and CGM-Baseline Use Subgroups in the International Diabetes Closed-Loop TrialLaya Ekhlaspour, Dan Raghinaru, Gregory P Forlenza, et al.
Clinical Diabetes : a Publication of the American Diabetes Association|January 17, 2024
Beneficial Effects of Control-IQ Automated Insulin Delivery in Basal-Bolus and Basal-Only Insulin Users With Type 2 DiabetesCarol J Levy, Dan Raghinaru, Yogish C Kudva, et al.
Pediatric Diabetes|July 13, 2016
Ketone production in children with type 1 diabetes, ages 4-14 years, with and without nocturnal insulin pump suspensionR Paul Wadwa, H Peter Chase, Dan Raghinaru, et al.
Diabetes Technology & Therapeutics|June 11, 2021
Patient-Reported Outcomes in a Randomized Trial of Closed-Loop Control: The Pivotal International Diabetes Closed-Loop TrialYogish C Kudva, Lori M Laffel, Sue A Brown, et al.
Ophthalmology|November 20, 2013
Donor age and factors related to endothelial cell loss 10 years after penetrating keratoplasty: Specular Microscopy Ancillary Study, Jonathan H Lass, Beth Ann Benetz, et al.
JAMA Ophthalmology|October 17, 2014
Factors associated with corneal graft survival in the cornea donor study, Alan Sugar, Robin L Gal, et al.
Pageof 5